{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:58:00Z","timestamp":1792267080255,"version":"4.4.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The treatment for Glioblastoma is limited due to the presence of the blood brain barrier, which restricts the entry of chemotherapeutic drugs into the brain. Local delivery into the tumor resection margin has the potential to improve efficacy of chemotherapy. We developed a safe and clinically translatable irinotecan implant for local delivery to increase its efficacy while minimizing systemic side effects. Irinotecan-loaded implants were manufactured using hot melt extrusion, gamma sterilized at 25\u00a0kGy, and characterized for their irinotecan content, release, and drug diffusion. Their therapeutic efficacy was evaluated in a patient-derived xenograft mouse resection model of glioblastoma. Their safety and translatability were evaluated using histological analysis of brain tissue and serum chemistry analysis. Implants containing 30% and 40% w\/w irinotecan were manufactured without plasticizer. The 30% and 40% implants showed moderate local toxicity up to 2- and 6-day post-implantation. Histopathology of the implantation site showed signs of necrosis at days 45 and 14 for the 30% and 40% implants. Hematological analysis and clinical chemistry showed no signs of serious systemic toxicity for either implant. The 30% implants had an 80% survival at day 148, with no sign of tumor recurrence. Gamma sterilization and 12-month storage had no impact on the integrity of the 30% implants. This study demonstrates that the 30% implants are a promising novel treatment for glioblastoma that could be quickly translated into the clinic.<\/jats:p>\n                <jats:p><jats:bold>Graphical Abstract<\/jats:bold><\/jats:p>","DOI":"10.1007\/s13346-024-01524-x","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T15:03:45Z","timestamp":1707231825000},"page":"3070-3088","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Local administration of irinotecan using an implantable drug delivery device stops high-grade glioma tumor recurrence in a glioblastoma tumor model"],"prefix":"10.1007","volume":"14","author":[{"given":"Dina","family":"Abdelnabi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Lastakchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Hingtgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Valdivia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0750-9080","authenticated-orcid":false,"given":"Christopher","family":"McConville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,6]]},"reference":[{"key":"1524_CR1","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.3390\/cancers14102412","volume":"14","author":"S Grochans","year":"2022","unstructured":"Grochans S, Cybulska AM, Siminska D, Korbecki J, Kojder K, Chlubek D, et al. Epidemiology of glioblastoma multiforme\u2013literature review. Cancers. 2022;14:2412.","journal-title":"Cancers"},{"key":"1524_CR2","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO Classification Of Tumors Of The Central Nervous System: a summary. Neuro Oncol. 2021;23:1231\u201351.","journal-title":"Neuro Oncol"},{"key":"1524_CR3","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131:803\u201320.","journal-title":"Acta Neuropathol"},{"key":"1524_CR4","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1007\/s12094-016-1497-x","volume":"18","author":"PD Delgado-Lopez","year":"2016","unstructured":"Delgado-Lopez PD, Corrales-Garc\u00eda EM. Survival in glioblastoma: a review on the impact of treatment modalities. Clin Transl Oncol. 2016;18:1062\u201371.","journal-title":"Clin Transl Oncol"},{"key":"1524_CR5","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1016\/j.wneu.2017.09.104","volume":"109","author":"D Nizamutdinov","year":"2018","unstructured":"Nizamutdinov D, Stock EM, Dandashi JA, Vasquez EA, Mao Y, Dayawansa S, et al. Prognostication of survival outcomes in patients diagnosed with glioblastoma. World Neurosurg. 2018;109:e67-74.","journal-title":"World Neurosurg"},{"key":"1524_CR6","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S1470-2045(06)70665-9","volume":"7","author":"W Stummer","year":"2006","unstructured":"Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006;7:392\u2013401.","journal-title":"Lancet Oncol"},{"key":"1524_CR7","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.3171\/2015.5.JNS1577","volume":"124","author":"D Lau","year":"2016","unstructured":"Lau D, Hervey-Jumper SL, Chang S, Molinaro AM, McDermott MW, Phillips JJ, et al. A prospective phase II clinical trial of 5-aminolevulinic acid to assess the correlation of intraoperative fluorescence intensity and degree of histologic cellularity during resection of high-grade gliomas. J Neurosurg. 2016;124:1300\u20139.","journal-title":"J Neurosurg"},{"key":"1524_CR8","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987\u201396.","journal-title":"N Engl J Med"},{"key":"1524_CR9","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.neo.2018.05.001","volume":"20","author":"MC de Gooijer","year":"2018","unstructured":"de Gooijer MC, de Vries NA, Buckle T, Buil LCM, Beijnen JH, Boogerd W, et al. Improved brain penetration and antitumor efficacy of temozolomide by inhibition of ABCB1 and ABCG2. Neoplasia. 2018;20:710\u201320.","journal-title":"Neoplasia"},{"key":"1524_CR10","doi-asserted-by":"publisher","first-page":"3728","DOI":"10.1158\/1078-0432.CCR-03-0807","volume":"10","author":"S Ostermann","year":"2004","unstructured":"Ostermann S, Csajka C, Buclin T, Leyvraz S, Lejeune F, Decosterd LA, et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res. 2004;10:3728\u201336.","journal-title":"Clin Cancer Res"},{"key":"1524_CR11","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1016\/j.celrep.2017.05.014","volume":"19","author":"AE Calvert","year":"2017","unstructured":"Calvert AE, Chalastanis A, Wu Y, Hurley LA, Kouri FM, Bi Y, et al. Cancer-associated IDH1 promotes growth and resistance to targeted therapies in the absence of mutation. Cell Rep. 2017;19:1858\u201373.","journal-title":"Cell Rep"},{"key":"1524_CR12","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1200\/JCO.2008.18.8417","volume":"27","author":"JA Quinn","year":"2009","unstructured":"Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, et al. Phase II trial of temozolomide plus O6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol. 2009;27:1262\u20137.","journal-title":"J Clin Oncol"},{"key":"1524_CR13","first-page":"1008","volume":"345","author":"H Brem","year":"1995","unstructured":"Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group Lancet. 1995;345:1008\u201312.","journal-title":"The Polymer-brain Tumor Treatment Group Lancet"},{"key":"1524_CR14","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1093\/neuonc\/5.2.79","volume":"5","author":"M Westphal","year":"2003","unstructured":"Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003;5:79\u201388.","journal-title":"Neuro Oncol"},{"key":"1524_CR15","doi-asserted-by":"crossref","unstructured":"Hart MG, Grant R, Garside R, Rogers G, Somerville M, Stein K. Chemotherapy wafers for high grade glioma. Cochrane Database Syst Rev 2011;3:CD007294.","DOI":"10.1002\/14651858.CD007294.pub2"},{"key":"1524_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2020.05.012","volume":"324","author":"M Gawley","year":"2020","unstructured":"Gawley M, Almond L, Daniel S, Lastakchi S, Kaur S, Detta A, et al. Development and in vivo evaluation of Irinotecan-loaded Drug Eluting Seeds (iDES) for the localised treatment of recurrent glioblastoma multiforme. J Control Release. 2020;324:1\u201316.","journal-title":"J Control Release"},{"key":"1524_CR17","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/bmc.1345","volume":"24","author":"M Ramesh","year":"2010","unstructured":"Ramesh M, Ahlawat P, Srinivas N. Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed Chromatogr. 2010;24:104\u201323.","journal-title":"Biomed Chromatogr"},{"key":"1524_CR18","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1093\/annonc\/mdf337","volume":"13","author":"Y Xu","year":"2002","unstructured":"Xu Y. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol. 2002;13:1841\u201351.","journal-title":"Ann Oncol"},{"key":"1524_CR19","unstructured":"Sinha B. Topoisomerase Inhibitors. A review of their therapeutic potential in cancer. Drugs 1995; 23:831\u201336."},{"key":"1524_CR20","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1215\/15228517-2008-075","volume":"11","author":"J Vrendenburgh","year":"2009","unstructured":"Vrendenburgh J, Desjardins A, Reardon DA, Friedman HS. Experience with irinotecan for the treatment of malignant glioma. Neuro Oncol. 2009;11:80\u20139.","journal-title":"Neuro Oncol"},{"key":"1524_CR21","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/sj.bjc.6603233","volume":"95","author":"A Saunders","year":"2006","unstructured":"Saunders A, Iveson T. Management of advanced colorectal cancer: state of the art. Br J Cancer. 2006;95:131\u20138.","journal-title":"Br J Cancer"},{"key":"1524_CR22","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1200\/JCO.1999.17.5.1516","volume":"17","author":"HS Friedman","year":"1999","unstructured":"Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol. 1999;17:1516\u201325.","journal-title":"J Clin Oncol"},{"key":"1524_CR23","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1093\/neuonc\/4.2.102","volume":"4","author":"CD Turner","year":"2004","unstructured":"Turner CD, Gururangan S, Eastwood J, Bottom K, Watral W, Beason R, et al. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. Neuro Oncol. 2004;4:102\u20138.","journal-title":"Neuro Oncol"},{"key":"1524_CR24","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1097\/00000421-200204000-00022","volume":"25","author":"TF Cloughesy","year":"2002","unstructured":"Cloughesy TF, Filka E, Nelson G, Kabbinavar F, Friedman H, Miller LL, et al. Irinotecan treatment for recurrent malignant glioma using an every-three-week regimen. Am J Clin Oncol. 2002;25:204\u20138.","journal-title":"Am J Clin Oncol"},{"key":"1524_CR25","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1002\/cncr.11304","volume":"97","author":"JC Buckner","year":"2003","unstructured":"Buckner JC, Reid JM, Wright K, Kaufmann SH, Erlichman C, Ames M, et al. Irinotecan in the treatment of glioma patients: current and future studies of the North Central Cancer Treatment Group. Cancer. 2003;97:2352\u20138.","journal-title":"Cancer"},{"key":"1524_CR26","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1093\/annonc\/mdg159","volume":"14","author":"E Raymond","year":"2003","unstructured":"Raymond E, Fabbro M, Boige V, Rixe O, Frenay M, Vassal G, et al. Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naive patients with glioblastoma. Ann Oncol. 2003;14:603\u201314.","journal-title":"Ann Oncol"},{"key":"1524_CR27","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1023\/A:1014532202188","volume":"56","author":"MC Chamberlain","year":"2002","unstructured":"Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. J Neurooncol. 2002;56:183\u20138.","journal-title":"J Neurooncol"},{"key":"1524_CR28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1215\/S1152851703000218","volume":"6","author":"TT Batchelor","year":"2004","unstructured":"Batchelor TT, Gilbert MR, Supko JG, Carson KA, Nabors LB, Grossman SA, et al. Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97\u201311. Neuro Oncol. 2004;6:21\u20137.","journal-title":"Neuro Oncol"},{"key":"1524_CR29","first-page":"2940","volume":"9","author":"MR Gilbert","year":"2003","unstructured":"Gilbert MR, Supko JG, Batchelor T, Lesser G, Fisher JD, Piantadosi S, et al. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res. 2003;9:2940\u20139.","journal-title":"Clin Cancer Res"},{"key":"1524_CR30","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1200\/jco.2005.23.16_suppl.1521","volume":"23","author":"WKA Yung","year":"2005","unstructured":"Yung WKA, Lieberman FS, Wen P, Robin I, Gilbert M, Chang S, et al. Combination of temozolomide (TMZ) and irinotecan (CPT-11) showed enhanced activity for recurrent malignant gliomas: A North American Brain Tumor Consortium (NABTC) phase II study. J Clin Oncol. 2005;23:1521\u2013621.","journal-title":"J Clin Oncol"},{"key":"1524_CR31","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/01.coc.0000045852.88461.80","volume":"27","author":"ML Gruber","year":"2004","unstructured":"Gruber ML, Buster WP. Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma. Am J Clin Oncol. 2004;27:33\u20138.","journal-title":"Am J Clin Oncol"},{"key":"1524_CR32","doi-asserted-by":"publisher","first-page":"4779","DOI":"10.1200\/JCO.2004.06.181","volume":"22","author":"AA Brandes","year":"2004","unstructured":"Brandes AA, Tosoni A, Basso U, Reni M, Valduga F, Monfardini S, et al. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol. 2004;22:4779\u201386.","journal-title":"J Clin Oncol"},{"key":"1524_CR33","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1215\/S1152851703000498","volume":"6","author":"JA Quinn","year":"2004","unstructured":"Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Vredenburgh J, et al. Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. Neuro Oncol. 2004;6:145\u201353.","journal-title":"Neuro Oncol"},{"key":"1524_CR34","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1215\/S1152851703000413","volume":"6","author":"DA Reardon","year":"2004","unstructured":"Reardon DA, Quinn JA, Rich JN, Gururangan S, Vredenburgh J, Sampson JH, et al. Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. Neuro Oncol. 2004;6:134\u201344.","journal-title":"Neuro Oncol"},{"key":"1524_CR35","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.hoc.2004.05.003","volume":"18","author":"B Purow","year":"2004","unstructured":"Purow B, Fine HA. Antiangiogenic therapy for primary and metastatic brain tumors. Hematol Oncol Clin North Am. 2004;18:1161\u201381.","journal-title":"Hematol Oncol Clin North Am"},{"key":"1524_CR36","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1158\/1078-0432.CCR-06-2309","volume":"13","author":"JJ Vredenburgh","year":"2007","unstructured":"Vredenburgh JJ, Desjardins A, Herndon JE, Dowell JM, Reardon DA, Quinn JA, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas. Clin Cancer Res. 2007;13:1253\u20139.","journal-title":"Clin Cancer Res"},{"key":"1524_CR37","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1200\/jco.2007.25.18_suppl.2003","volume":"18","author":"KJ Goli","year":"2007","unstructured":"Goli KJ, Desjardins A, Herndon JE, Rich JN, Reardon DA, Quinn JA, et al. Phase II trial of bevacizumab and irinotecan in the treatment of malignant gliomas. J Clin Oncol. 2007;18:2003\u2013103.","journal-title":"J Clin Oncol"},{"key":"1524_CR38","doi-asserted-by":"publisher","first-page":"4722","DOI":"10.1200\/JCO.2007.12.2440","volume":"25","author":"JJ Vredenburgh","year":"2007","unstructured":"Vredenburgh JJ, Desjardins A, Herndon JE, Marcello J, Reardon DA, Quinn JA, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25:4722\u20139.","journal-title":"J Clin Oncol"},{"key":"1524_CR39","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1200\/jco.2007.25.18_suppl.2078","volume":"25","author":"S Raval","year":"2007","unstructured":"Raval S, Hwang S, Dorsett L. Bevacizumab and irinotecan in patients (pts) with recurrent glioblastoma multiforme (GBM). J Clin Oncol. 2007;25:2078\u2013178.","journal-title":"J Clin Oncol"},{"key":"1524_CR40","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1002\/cncr.23401","volume":"112","author":"F Bokstein","year":"2008","unstructured":"Bokstein F, Shpigel S, Blumenthal DT. Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer. 2008;112:2267\u201373.","journal-title":"Cancer"},{"key":"1524_CR41","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","volume":"1","author":"HS Friedman","year":"2009","unstructured":"Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;1:4733\u201340.","journal-title":"J Clin Oncol"},{"key":"1524_CR42","doi-asserted-by":"publisher","first-page":"80","DOI":"10.2478\/raon-2014-0021","volume":"49","author":"T Mesti","year":"2015","unstructured":"Mesti T, Moltara ME, Boc M, Rebersek M, Ocvirk J. Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience. Radiol Oncol. 2015;49:80\u20135.","journal-title":"Radiol Oncol"},{"key":"1524_CR43","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jons.2016.07.009","volume":"2","author":"O Ozel","year":"2016","unstructured":"Ozel O, Kurt M, Ozdemir O, Bayram J, Akdeniz H, Koca D. Complete response to bevacizumab plus irinotecan in patients with rapidly progressive GBM: Cases report and literature review. J Oncol Sci. 2016;2:87\u201394.","journal-title":"J Oncol Sci"},{"key":"1524_CR44","first-page":"73","volume":"12","author":"JR Hecht","year":"1998","unstructured":"Hecht JR. Gastrointestinal toxicity of irinotecan. Oncology. 1998;12:73\u20138.","journal-title":"Oncology"},{"key":"1524_CR45","doi-asserted-by":"crossref","unstructured":"G. Cruickshank, O. Fayeye, D. Ngoga, Connor J, Detta A. Intraoperative intraparenchymal injection of irinotecan drug loaded beads in patients with recurrent glioblastoma (GBM): a safe new and depot approach for loco-reginal therapy (NCT02433392). Neurol Oncol 2015;17:v11.","DOI":"10.1093\/neuonc\/nov205.05"},{"key":"1524_CR46","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1158\/0008-5472.CAN-08-3886","volume":"69","author":"H Wakimoto","year":"2009","unstructured":"Wakimoto H, Kesari S, Farrell CJ, Curry WTJ, Zaupa C, et al. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res. 2009;69:3472\u201381.","journal-title":"Cancer Res"},{"key":"1524_CR47","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.ymthe.2020.02.008","volume":"28","author":"KT Sheets","year":"2020","unstructured":"Sheets KT, Ewend MG, Mohiti-Asli M, Tuin SA, Loboa EG, Aboody KS, et al. Developing implantable scaffolds to enhance neural stem cell therapy for post-operative glioblastoma. Mol Ther. 2020;28:1056\u201367.","journal-title":"Mol Ther"},{"key":"1524_CR48","first-page":"9","volume":"1","author":"F Pervin","year":"2011","unstructured":"Pervin F, Chen WW. Mechanically similar gel simulants for brain tissues. Dynam Behav Mat. 2011;1:9\u201313.","journal-title":"Dynam Behav Mat"},{"key":"1524_CR49","doi-asserted-by":"crossref","unstructured":"R. Galli, E. Binda, U. Orfanelli, B. Cipelletti, A. Gritti, S. De Vitis, et al. Vescovi. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004;64:7011\u201321.","DOI":"10.1158\/0008-5472.CAN-04-1364"},{"key":"1524_CR50","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature03128","volume":"432","author":"SK Singh","year":"2004","unstructured":"Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature. 2004;432:396\u2013401.","journal-title":"Nature"},{"key":"1524_CR51","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ejpb.2005.11.007","volume":"63","author":"W Friess","year":"2006","unstructured":"Friess W, Schlapp M. Sterilization of gentamicin containing collagen\/PLGA microparticle composites. Eur J Pharm Biopharm. 2006;63:176\u201387.","journal-title":"Eur J Pharm Biopharm"},{"key":"1524_CR52","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1208\/s12249-009-9226-1","volume":"10","author":"S Puthli","year":"2009","unstructured":"Puthli S, Vavia P. Formulation and performance characterization of radio-sterilized \u201cprogestin-only\u201d microparticles intended for contraception. AAPS PharmSciTech. 2009;10:443\u201352.","journal-title":"AAPS PharmSciTech"},{"key":"1524_CR53","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0939-6411(03)00104-8","volume":"56","author":"N Faisant","year":"2003","unstructured":"Faisant N, Siepmann J, Richard J, Benoit J. Mathematical modeling of drug release from bioerodible microparticles: effect of gamma-irradiation. Eur J Pharm Biopharm. 2003;56:271\u20139.","journal-title":"Eur J Pharm Biopharm"},{"key":"1524_CR54","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0168-3659(99)00118-2","volume":"61","author":"D Mohr","year":"1999","unstructured":"Mohr D, Wolff M, Kissel T. Gamma irradiation for terminal sterilization of 17beta-estradiol loaded poly-(D, L-lactide-co-glycolide) microparticles. J Con Rel. 1999;61:203\u201317.","journal-title":"J Con Rel"},{"key":"1524_CR55","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1200\/JCO.1997.15.1.251","volume":"15","author":"P Rougier","year":"1997","unstructured":"Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol. 1997;15:251\u201360.","journal-title":"J Clin Oncol"},{"key":"1524_CR56","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1200\/JCO.1996.14.4.1128","volume":"14","author":"ML Rothenberg","year":"1996","unstructured":"Rothenberg ML, Eckardt JR, Kuhn JG, Burris HA, Nelson J, Hilsenbeck SG, et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol. 1996;14:1128\u201335.","journal-title":"J Clin Oncol"},{"key":"1524_CR57","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1742-7843.2007.00068.x","volume":"100","author":"N Kopjar","year":"2007","unstructured":"Kopjar N, Zeljezi\u0107 D, Vrdoljak AL, Radi\u0107 B, Rami\u0107 S, Mili\u0107 M, et al. Irinotecan toxicity to human blood cells in vitro: relationship between various biomarkers. Basic Clin Pharmacol Toxicol. 2007;100:403\u201313.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"1524_CR58","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.lungcan.2004.12.002","volume":"48","author":"HL Kindler","year":"2005","unstructured":"Kindler HL, Herndon JE, Zhang C, Green MR. Cancer and Leukemia Group B Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B. Lung Cancer. 2005;48:423\u20138.","journal-title":"Lung Cancer"},{"key":"1524_CR59","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1200\/JCO.1992.10.1.16","volume":"10","author":"M Fukuoka","year":"2006","unstructured":"Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol. 2006;10:16\u201320.","journal-title":"J Clin Oncol"},{"key":"1524_CR60","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/clpt.2008.152","volume":"85","author":"N Yamamoto","year":"2009","unstructured":"Yamamoto N, Takahashi T, Kunikane H, Masuda N, Eguchi K, Shibuya M, et al. Phase I\/II pharmacokinetic and pharmacogenomic study of UGT1A1 polymorphism in elderly patients with advanced non-small cell lung cancer treated with irinotecan. Clin Pharmacol Ther. 2009;85:149\u201354.","journal-title":"Clin Pharmacol Ther"},{"key":"1524_CR61","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/sj.clpt.6100513","volume":"84","author":"FA de Jong","year":"2008","unstructured":"de Jong FA, van der Bol JM, Mathijssen RHJ, van Gelder T, Wiemer EAC, Sparreboom A, et al. Renal function as a predictor of irinotecan-induced neutropenia. Clin Pharmacol Ther. 2008;84:254\u201362.","journal-title":"Clin Pharmacol Ther"},{"key":"1524_CR62","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2147\/TCRM.S248441","volume":"16","author":"SK Oh","year":"2020","unstructured":"Oh SK, Lim BG, Kim YS, Kim SS. Comparison of the postoperative liver function between total intravenous anesthesia and inhalation anesthesia in patients with preoperatively elevated liver transaminase levels: a retrospective cohort study. Ther Clin Risk Manag. 2020;16:223\u201332.","journal-title":"Ther Clin Risk Manag"},{"key":"1524_CR63","first-page":"350","volume":"47","author":"RB Patel","year":"2011","unstructured":"Patel RB, Solorio L, Wu H, Krupka T, Exner AA. Effect of injection site on in situ implant formation and drug release in vivo. J Con Release. 2011;47:350\u20138.","journal-title":"J Con Release"},{"key":"1524_CR64","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3390\/bioengineering8120205","volume":"8","author":"A Fayzullin","year":"2021","unstructured":"Fayzullin A, Bakulina A, Mikaelyan K, Shekhter A, Guller A. Implantable drug delivery systems and foreign body reaction: traversing the current clinical landscape. Bioengineering. 2021;8:205.","journal-title":"Bioengineering"},{"key":"1524_CR65","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1021\/acsnano.1c07649","volume":"16","author":"GD Cha","year":"2022","unstructured":"Cha GD, Lee WH, Sunwoo SH, Kang D, Kang T, Cho KW, et al. Multifunctional injectable hydrogel for in vivo diagnostic and therapeutic applications. ACS Nano. 2022;16:554\u201367.","journal-title":"ACS Nano"},{"key":"1524_CR66","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1308\/003588414X13946184903568","volume":"96","author":"SJ Smith","year":"2014","unstructured":"Smith SJ, Rahman CV, Clarke PA, Ritchie AA, Gould TW, Ward JH, et al. Surgical delivery of drug releasing poly(lactic-co-glycolic acid)\/poly(ethylene glycol) paste with in vivo effects against glioblastoma. Ann R Coll Surg Engl. 2014;96:495\u2013501.","journal-title":"Ann R Coll Surg Engl"},{"key":"1524_CR67","doi-asserted-by":"publisher","first-page":"2100425","DOI":"10.1002\/adma.202100425","volume":"33","author":"Y Lee","year":"2021","unstructured":"Lee Y, Kang T, Cho HR, Lee GJ, Park OK, Kim S, et al. Localized delivery of theranostic nanoparticles and high-energy photons using microneedles-on-bioelectronics. Adv Mater. 2021;33:2100425.","journal-title":"Adv Mater"},{"key":"1524_CR68","doi-asserted-by":"crossref","unstructured":"Hern\u00e1n P\u00e9rez de la Ossa D, Lorente M, Gil-Alegre ME, Torres S, Garc\u00eda-Taboada E, Aberturas Mdel R, et al. Local delivery of cannabinoid-loaded microparticles inhibits tumor growth in a murine xenograft model of glioblastoma multiforme. PLoS One. 2013;8:e54795.","DOI":"10.1371\/journal.pone.0054795"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-024-01524-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-024-01524-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-024-01524-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T15:12:42Z","timestamp":1727795562000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-024-01524-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,6]]},"references-count":68,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1524"],"URL":"https:\/\/doi.org\/10.1007\/s13346-024-01524-x","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,6]]},"assertion":[{"value":"16 January 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of University of North Carolina. The in vivo toxicity and efficacy studies adhered to the NIH Guide for the Care and Use of Laboratory Animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"N\/A.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}